Department of Chemistry, The University of Chicago, Chicago, United States; Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University of Chicago, Chicago, United States
Department of Chemistry, The University of Chicago, Chicago, United States; Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University of Chicago, Chicago, United States
Department of Chemistry, The University of Chicago, Chicago, United States; Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University of Chicago, Chicago, United States
Simona Martin
Department of Chemistry, The University of Chicago, Chicago, United States; Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University of Chicago, Chicago, United States
Jihad Aburas
Department of Neurobiology, The University of Chicago, Chicago, United States
Recombinant Antibody Platform (TAb-IP), Institut Curie, PSL Research University, CNRS UMR144, Paris, France; Cell Biology and Cancer Unit, Institut Curie, PSL Research University, CNRS UMR144, Paris, France
Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University of Chicago, Chicago, United States; Department of Neurobiology, The University of Chicago, Chicago, United States
Department of Chemistry, The University of Chicago, Chicago, United States; Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University of Chicago, Chicago, United States
Nucleic acid nanodevices present great potential as agents for logic-based therapeutic intervention as well as in basic biology. Often, however, the disease targets that need corrective action are localized in specific organs, and thus realizing the full potential of DNA nanodevices also requires ways to target them to specific cell types in vivo. Here, we show that by exploiting either endogenous or synthetic receptor-ligand interactions and leveraging the biological barriers presented by the organism, we can target extraneously introduced DNA nanodevices to specific cell types in Caenorhabditis elegans, with subcellular precision. The amenability of DNA nanostructures to tissue-specific targeting in vivo significantly expands their utility in biomedical applications and discovery biology.